[The effects and new insights of ARB on CKD management].
Increasing number of patients suffer from chronic kidney disease (CKD) all over the world. CKD is a risk factor of cardiovascular disease as well as end-stage renal disease. The strategy to reduce CKD patients is pivotal for public health. The most useful treatment is to control blood pressure. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are now recommended as the first choice. The recent clinical studies have provided more and more evidence that ARB is effective for CKD management. A part of mechanisms is beyond blood pressure lowering. Oxidative stress and inflammation may be involved in the mechanisms.
Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine.
Takashi
T
Nakamichi
Sadayoshi
S
Itoh
D057911:Angiotensin Receptor Antagonists; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*
D057911:Angiotensin Receptor Antagonists